Table 3.

Best Overall Response to ICI Monotherapy According to RECIST 1.1 in the Subgroup With and Without Massive Lesions

	Total (n = 263)	max BTS ≤ 50 mm (n = 135)	max BTS > 50 mm (n = 128)	p
CR, %	0.4	0.7	0.0	–
PR, %	25.9	26.7	25.0	0.78
SD, %	28.5	38.5	18.0	< 0.001
PD, %	41.4	29.6	53.9	< 0.001
ORR, %	26.3	27.4	25.0	0.78
DCR, %	54.4	65.9	43.0	< 0.001

ICI immune checkpoint inhibitor; RECIST 1.1 response evaluation criteria in solid tumors guidelines version 1.1, BTS baseline tumor size, CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR overall response rate, DCR disease control rate